Search Results

• Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  Umbrella Long-Term Follow-Up Protocol

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse

• Tipifarnib and Naxitamab for Relapsed/​Refractory Neuroblastoma

  Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

  Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

• Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

  Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

• Beat Childhood Cancer Specimen Banking and Data Registry

  Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers

• Mechanical Properties and Esophageal Fibrosis in Eosinophilic Esophagitis

  Mechanical Properties and Esophageal Fibrosis in Eosinophilic Esophagitis

• Project:EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study

  Project: EveryChild a Registry, Eligibility Screening, Biology and Outcome Study

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy